EDITOR,-Ophthalmic involvement in patients with AIDS occurs in more than 90% of cases at postmortem examination.' It is characterised both by infectious manifestations (HIV retinitis, cytomegalovirus retinitis, Pneumocystis carinii choroiditis, fungal choroiditis, toxoplasmosis) and by noninfectious manifestations (eyelid Kaposi's sarcoma, retinal microvasculopathy, keratoconjunctivitis sicca2). Cytomegalovirus (CMV) retinitis is the most common severe ocular complication occurring as a late manifestation with severe CD4 lymphocyte depletion.
We Investigations showed an erythrocyte sedimentation rate of 10 mm/h (normal range 1-12), a white blood count of 8XI09/l (normal range 4-11 x 109/1) with a normal differential count. CD4 lymphocyte count was 355X106/1 (normal range 600-1950X106/l), CD8 lymphocyte count was 967X 106/1 (normal range 300-1 100X 106/1), Agp24 was positive and ,B2 microglobulin 5-15 mg/l (normal range 0-75-1-75 mg/l). On the basis of the clinical appearance of the left fundus a CMV retinitis was suspected. We administered foscamet intravenously (60 mg/kg every 8 hours for 3 weeks) followed by a maintenance dose (90 mg/kg/day). In view of the CD4 lymphocyte count an anterior chamber tap was performed. Results were positive for local production of anti-CMV immunoglobulins; Goldmann-Witmer coefficient was 4-12 for CMV, 2-02 for herpes simplex virus, and not calculable for varicella zoster virus. Early CMV antigen was detected in the urine. After 5 weeks of treatment resolution of the active retinitis in the left eye had occurred (Fig 2) .
The patient decided to discontinue the therapy. After 1 month a reactivation of macular infection was noted (Fig 3) . CD4 lymphocyte count was 259X 106/1, CD8 lymphocyte count was 818X 106/1, Agp24 was positive and 02 microglobulin 3-88 mg/I. We again administered foscamet intravenously (60 mg/kg every 8 hours for 3 weeks) on admission. After 5 weeks of treatment resolution of the CMV retinitis was observed; maintenance foscamet therapy was continued. 
